Thermo Fisher Scientific Inc. (NYSE:TMO) is Parsons Capital Management Inc. RI’s 10th Largest Position

Parsons Capital Management Inc. RI cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 0.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,730 shares of the medical research company’s stock after selling 125 shares during the period. Thermo Fisher Scientific comprises approximately 1.4% of Parsons Capital Management Inc. RI’s portfolio, making the stock its 10th largest position. Parsons Capital Management Inc. RI’s holdings in Thermo Fisher Scientific were worth $19,496,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Halpern Financial Inc. lifted its stake in Thermo Fisher Scientific by 307.7% in the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock worth $27,000 after purchasing an additional 40 shares during the last quarter. Coppell Advisory Solutions LLC bought a new stake in Thermo Fisher Scientific in the second quarter worth $33,000. Live Oak Investment Partners bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $36,000. Tyler Stone Wealth Management bought a new stake in Thermo Fisher Scientific in the second quarter worth $37,000. Finally, Indiana Trust & Investment Management CO bought a new stake in Thermo Fisher Scientific in the third quarter worth $38,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 over the last 90 days. 0.32% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Down 1.3 %

TMO traded down $7.69 during midday trading on Monday, reaching $573.52. The company’s stock had a trading volume of 188,757 shares, compared to its average volume of 1,595,220. The firm has a market capitalization of $218.69 billion, a price-to-earnings ratio of 37.17, a PEG ratio of 2.44 and a beta of 0.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The stock’s 50-day moving average is $566.46 and its 200-day moving average is $521.25.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The business had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business’s revenue was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.40 earnings per share. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date is Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

Analysts Set New Price Targets

TMO has been the subject of several recent research reports. Barclays downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price objective for the company. HSBC started coverage on shares of Thermo Fisher Scientific in a research note on Monday, December 18th. They set a “buy” rating and a $610.00 price objective for the company. Robert W. Baird reaffirmed an “outperform” rating and set a $670.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. Finally, TheStreet raised shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $599.00.

View Our Latest Research Report on Thermo Fisher Scientific

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.